Superworth

Regeneron Pharmaceuticals price to book ratio REGN

Market value divided by the book value of the company's net assets, since 2010.

Today, Nov 3, 2026
3.2×
10-year median
4.0×
Against its 10-year history
21st
percentile: 0 is its lowest day, 100 its highest
10-year range
1.8× to 11.3×
Peer median
6.8×

Regeneron Pharmaceuticals' price to book ratio is 3.2× as of Nov 3, 2026.

That is below its ten-year median of 4.0×, lower than on 79% of days in the last ten years.

Over that time it ranged from 1.8× in May 2025 to 11.3× in Jun 2017.

The median for 9 biotech stocks of a similar size is 6.8×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far3.1×2.0×3.1×
20252.7×1.8×2.7×
20242.7×2.6×4.7×
20233.8×3.2×4.0×
20223.7×3.1×4.3×
20213.9×3.8×5.7×
20205.1×3.5×7.3×
20193.9×3.1×5.9×
20185.0×4.7×6.8×
20176.7×6.6×11.3×
20168.6×8.0×15.5×
201517.1×14.9×19.7×
201416.5×12.7×17.6×
201316.3×12.5×21.7×
201220.1×13.9×25.8×
201111.7×6.2×12.4×
20107.6×4.9×7.7×

Against its peers

Companies in Biotechnology nearest Regeneron Pharmaceuticals' size, closest first, today.

CompanyPrice to book ratio
REGNRegeneron Pharmaceuticals3.2×
VRTXVertex Pharmaceuticals6.8×
ONCBeOne Medicines7.8×
UTHRUnited Therapeutics4.0×
INCYIncyte3.8×
ALNYAlnylam Pharmaceuticals15.7×
EXELExelixis9.4×
NBIXNeurocrine Biosciences4.0×
HALOHalozyme Therapeutics102×
TECHBIO-TECHNE5.4×
Peer median6.8×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Regeneron Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.